Treatment of <i>Candida glabrata</i> Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin

Treatment of <i>Candida glabrata</i> Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin

ABSTRACT While Candida albicans remains the most common Candida isolate, Candida glabrata accounts for approximately 15 to 20% of all Candida infections in the United States. In this study we used immunosuppressed mice infected with C. glabrata to investigate the efficacy of liposomal amphotericin B...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Jon Olson, Jill Adler‐Moore, Peter J. Smith, Richard T. Proffitt
Hōputu:	Artigo
Reo:	Ingarihi
I whakaputaina:	2005
Urunga tuihono:	https://doi.org/10.1128/aac.49.12.4895-4902.2005
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

Treatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin
mā: Olson, Jon A., me ētahi atu.
I whakaputaina: (2005)

Caspofungin in Combination with Amphotericin B against Candida glabrata
mā: Barchiesi, Francesco, me ētahi atu.
I whakaputaina: (2005)

Killing Kinetics of Caspofungin, Micafungin, and Amphotericin B against Candida guilliermondii
mā: Cantón, Emilia, me ētahi atu.
I whakaputaina: (2006)

Micafungin versus caspofungin in the treatment of Candida glabrata infection: a case report
mā: Yamada, Shoko Merrit, me ētahi atu.
I whakaputaina: (2016)

Candida glabrata Mutants Demonstrating Paradoxical Reduced Caspofungin Susceptibility but Increased Micafungin Susceptibility
mā: Healey, Kelley R., me ētahi atu.
I whakaputaina: (2011)

Anidulafungin and Micafungin MIC Breakpoints Are Superior to That of Caspofungin for Identifying <i>FKS</i> Mutant Candida glabrata Strains and Echinocandin Resistance
mā: Ryan K. Shields, me ētahi atu.
I whakaputaina: (2013)

Comparison of the Fungicidal Activities of Caspofungin and Amphotericin B against Candida glabrata
mā: Barchiesi, Francesco, me ētahi atu.
I whakaputaina: (2005)

Differential <i>In Vivo</i> Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without <i>FKS</i> Resistance Mutations
mā: Maiken Cavling Arendrup, me ētahi atu.
I whakaputaina: (2012)

Posaconazole Activity against Candida glabrata after Exposure to Caspofungin or Amphotericin B
mā: Spreghini, Elisabetta, me ētahi atu.
I whakaputaina: (2008)

Effect of caspofungin and micafungin in combination with farnesol against Candida parapsilosis biofilms
mā: Renátó Kovács, me ētahi atu.
I whakaputaina: (2016)

Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations
mā: Arendrup, Maiken Cavling, me ētahi atu.
I whakaputaina: (2012)

Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata
mā: Spreghini, Elisabetta, me ētahi atu.
I whakaputaina: (2012)

Anidulafungin and Micafungin MIC Breakpoints Are Superior to That of Caspofungin for Identifying FKS Mutant Candida glabrata Strains and Echinocandin Resistance
mā: Shields, Ryan K., me ētahi atu.
I whakaputaina: (2013)

In Vitro Fungicidal Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis Evaluated by Time-Kill Studies
mā: Gil-Alonso, Sandra, me ētahi atu.
I whakaputaina: (2015)

Activities of Flucytosine, Fluconazole, Amphotericin B, and Micafungin in a Murine Model of Disseminated Infection by Candida glabrata
mā: Mariné, Marçal, me ētahi atu.
I whakaputaina: (2005)

Comparative Efficacies of Conventional Amphotericin B, Liposomal Amphotericin B (AmBisome), Caspofungin, Micafungin, and Voriconazole Alone and in Combination against Experimental Murine Central Nervous System Aspergillosis
mā: Clemons, Karl V., me ētahi atu.
I whakaputaina: (2005)

Comparative Efficacies of Conventional Amphotericin B, Liposomal Amphotericin B (AmBisome), Caspofungin, Micafungin, and Voriconazole Alone and in Combination against Experimental Murine Central Nervous System Aspergillosis
mā: Karl V. Clemons, me ētahi atu.
I whakaputaina: (2005)

Caspofungin in Combination with Amphotericin B against Candida parapsilosis
mā: Barchiesi, Francesco, me ētahi atu.
I whakaputaina: (2007)

Innate Inflammatory Response and Immunopharmacologic Activity of Micafungin, Caspofungin, and Voriconazole against Wild-Type and FKS Mutant Candida glabrata Isolates
mā: Beyda, Nicholas D., me ētahi atu.
I whakaputaina: (2015)

Comparison of the Physicochemical, Antifungal, and Toxic Properties of Two Liposomal Amphotericin B Products
mā: Jon Olson, me ētahi atu.
I whakaputaina: (2007)

Efficacies of Fluconazole, Caspofungin, and Amphotericin B in Candida glabrata-Infected p47(phox−/−) Knockout Mice
mā: Ju, Justina Y., me ētahi atu.
I whakaputaina: (2002)

Amphotericin B and Caspofungin Resistance in Candida glabrata Isolates Recovered from a Critically Ill Patient
mā: M. Krogh-Madsen, me ētahi atu.
I whakaputaina: (2006)

Successful therapy of Candida pulcherrima fungemia in a premature newborn with liposomal amphotericin B and micafungin
mā: Mpakosi, Alexandra, me ētahi atu.
I whakaputaina: (2016)

Antifungal Activity of Caspofungin in Combination with Amphotericin B against Candida glabrata: Comparison of Disk Diffusion, Etest, and Time-Kill Methods
mā: Kiraz, Nuri, me ētahi atu.
I whakaputaina: (2009)

Comparison of the Physicochemical, Antifungal, and Toxic Properties of Two Liposomal Amphotericin B Products
mā: Olson, Jon A., me ētahi atu.
I whakaputaina: (2008)

Liposomal Amphotericin B and Echinocandins as Monotherapy or Sequential or Concomitant Therapy in Murine Disseminated and Pulmonary Aspergillus fumigatus Infections
mā: Olson, Jon A., me ētahi atu.
I whakaputaina: (2010)

<i>In Vitro</i> Antifungal Combination of Flucytosine with Amphotericin B, Voriconazole, or Micafungin against Candida auris Shows No Antagonism
mā: Anne-Laure Bidaud, me ētahi atu.
I whakaputaina: (2019)

Multiple Intravitreal Liposomal Amphotericin B for a Case of Candida glabrata Endophthalmitis
mā: Sakai, Daiki, me ētahi atu.
I whakaputaina: (2021)

In Vitro Susceptibility of Invasive Isolates of <i>Candida</i> spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance
mā: Michael A. Pfaller, me ētahi atu.
I whakaputaina: (2007)

Global Surveillance of In Vitro Activity of Micafungin against <i>Candida</i> : a Comparison with Caspofungin by CLSI-Recommended Methods
mā: Michael A. Pfaller, me ētahi atu.
I whakaputaina: (2006)

Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies
mā: Denis Caillot, me ētahi atu.
I whakaputaina: (2007)

Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility
mā: Brzankalski, Gabriela E., me ētahi atu.
I whakaputaina: (2008)

Single-Dose AmBisome (Liposomal Amphotericin B) as Prophylaxis for Murine Systemic Candidiasis and Histoplasmosis
mā: Garcia, April, me ētahi atu.
I whakaputaina: (2000)

Combination of Posaconazole and Amphotericin B in the Treatment of Candida glabrata Biofilms
mā: Rodrigues, Célia F., me ētahi atu.
I whakaputaina: (2018)

Caspofungin and Liposomal Amphotericin B Therapy of Experimental Murine Scedosporiosis
mā: Bocanegra, Rosie, me ētahi atu.
I whakaputaina: (2005)

In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth
mā: Estelle Cateau, me ētahi atu.
I whakaputaina: (2008)

Assessment of the In Vitro Kinetic Activity of Caspofungin against Candida glabrata
mā: Nagappan, V., me ētahi atu.
I whakaputaina: (2010)

Correlation of MIC with Outcome for <i>Candida</i> Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints
mā: Michael A. Pfaller, me ētahi atu.
I whakaputaina: (2008)

Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to <i>Candida glabrata</i> Infection
mā: George R. Thompson, me ētahi atu.
I whakaputaina: (2008)

In Vivo Efficacy of Anidulafungin and Caspofungin against <i>Candida glabrata</i> and Association with In Vitro Potency in the Presence of Sera
mā: Nathan P. Wiederhold, me ētahi atu.
I whakaputaina: (2007)